Hercules Capital, Inc. (LON:0J4M)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.28B -6.9% |
| Revenue (ttm) | 427.98M +9.9% |
| Net Income | 266.73M +15.1% |
| EPS | 1.40 +6.6% |
| Shares Out | n/a |
| PE Ratio | 8.59 |
| Forward PE | 8.14 |
| Dividend | 1.41 (11.75%) |
| Ex-Dividend Date | Nov 10, 2026 |
| Volume | 3,604 |
| Open | 16.26 |
| Previous Close | 16.39 |
| Day's Range | 15.81 - 16.29 |
| 52-Week Range | 13.73 - 19.16 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Hercules Capital
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management ... [Read more]
Financial Performance
In 2025, Hercules Capital's revenue was $532.49 million, an increase of 7.88% compared to the previous year's $493.59 million. Earnings were $337.03 million, an increase of 29.56%.
Financial numbers in USD Financial StatementsNews
Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral ...
Hercules Capital Earnings Call Transcript: Q3 2026
Q3 NII of $87.3M covered the base distribution by 118%, while 9M income and originations set records. Stable credit, strong liquidity and normalized Q4 prepayments support expectations for higher income and continued platform growth.
Hercules Capital Earnings release: Q3 2026
Hercules Capital released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Hercules Capital Slides: Q3 2026
Hercules Capital has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Hercules Capital Quarterly report: Q3 2026
Hercules Capital has published its Q3 2026 quarterly earnings report on October 29, 2026.
Hercules Capital reports Q3 EPS 47c, consensus 48c
“Building on record results in the first half of 2026, the Hercules platform continued to deliver in Q3, bringing year-to-date new debt and equity commitments to a record $3.44 billion…
Hercules Capital Reports Third Quarter 2026 Financial Results
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Third Quarter 2026
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Announces Date for Release of Third Quarter 2026 Financial Results and Conference Call
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an upsized underwritten public offering o...
Rocket Pharmaceuticals secures $150M credit facility from Hercules Capital
Rocket Pharmaceuticals (RCKT) “announced that it has entered into a credit facility agreement with Hercules Capital (HTGC) for up to $150 million. The facility strengthens Rocket’s financial position ...
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening disea...
Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $400.0...
NorthStar secures up to $185M financing led by Hercules Capital
NorthStar Medical Technologies announced a multi-year growth capital facility of up to $185M with Hercules Capital (HTGC) to support NorthStar’s continued growth and expansion. The financing, includin...
NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies
BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technolo...
Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital's Investment Adviser Surpasses $2.3 Billion in Investable Capital
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty finance provider to innovative venture, gr...
Hercules Capital upgraded to Buy at UBS on better than average ROE
As previously reported, UBS upgraded Hercules Capital (HTGC) to Buy from Neutral with a price target of $18.50, up from $15.50, coming out of earnings for the business development company…
Hercules Capital upgraded to Buy from Neutral at UBS
UBS upgraded Hercules Capital (HTGC) to Buy from Neutral with an $18.50 price target
Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, ...
Hercules Capital price target lowered to $20 from $21 at Ladenburg
Ladenburg analyst Christopher Nolan lowered the firm’s price target on Hercules Capital (HTGC) to $20 from $21 and keeps a Buy rating on the shares.
Hercules Capital Earnings Call Transcript: Q2 2026
Record Q2 results included all-time highs in investment income and net investment income, with robust originations and strong portfolio credit quality. Liquidity and leverage improved, and the outlook remains positive with expectations for continued strong originations and normalized prepayments.
Hercules Capital Slides: Q2 2026
Hercules Capital has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Hercules Capital Earnings release: Q2 2026
Hercules Capital released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.